Oral Salmon Calcitonin Improves Fasting and Postprandial Glycemic Control in Lean Healthy Rats

 

 Buy Article Permissions and Reprints

Abstract

A novel oral form of salmon calcitonin (sCT) was recently demonstrated to improve both fasting and postprandial glycemic control and induce weight loss in diet-induced obese and insulin-resistant rats. To further explore the glucoregulatory efficacy of oral sCT, irrespective of obesity and metabolic dysfunction, the present study investigated the effect of chronic oral sCT treatment on fasting and postprandial glycemic control in male lean healthy rats. 20 male rats were divided equally into a control group receiving oral vehicle or an oral sCT (2 mg/kg) group. All rats were treated twice daily for 5 weeks. Body weight and food intake were monitored during the study period and fasting blood glucose, plasma insulin and insulin sensitivity were determined and an oral glucose tolerance test (OGTT) performed at study end. Compared with the vehicle group, rats receiving oral sCT had improved fasting glucose homeostasis and insulin resistance, as measured by homeostatic model assessment of insulin resistance index (HOMA-IR), with no change in body weight or fasting plasma insulin. In addition, the rats receiving oral sCT had markedly reduced glycemia and insulinemia during OGTT. This is the first report showing that chronic oral sCT treatment exerts a glucoregulatory action in lean healthy rats, irrespective of influencing body weight. Importantly, oral sCT seems to exert a dual treatment effect by improving fasting and postprandial glycemic control and insulin sensitivity. This and previous studies suggest oral sCT is a promising agent for the treatment of obesity-related insulin resistance and type 2 diabetes.

• References

• 1 Levitzky YS, Pencina MJ, D’Agostino RB, Meigs JB, Murabito JM, Vasan RS, Fox CS. Impact of impaired fasting glucose on cardiovascular disease: the Framingham Heart Study. J Am Coll Cardiol 2008; 51: 264-270
  CrossrefPubMedGoogle Scholar
• 2 Peter R, Okoseime OE, Rees A, Owens DR. Postprandial glucose – a potential therapeutic target to reduce cardiovascular mortality. Curr Vasc Pharmacol 2009; 7: 68-74
  CrossrefPubMedGoogle Scholar
• 3 Ning F, Tuomilehto J, Pyorala K, Onat A, Soderberg S, Qiao Q. Cardiovascular disease mortality in Europeans in relation to fasting and 2-h plasma glucose levels within a normoglycemic range. Diabetes Care 2010; 33: 2211-2216
  CrossrefPubMedGoogle Scholar
• 4 Israili ZH. Advances in the treatment of type 2 diabetes mellitus. Am J Ther 2011; 18: 117-152
  CrossrefPubMedGoogle Scholar
• 5 Blonde L. State of diabetes care in the United States. Am J Manag Care 2007; 13 (Suppl. 02) S36-S40
  PubMedGoogle Scholar
• 6 Blonde L. Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus. Cleve Clin J Med 2009; 76 (Suppl. 05) S4-S11
  CrossrefPubMedGoogle Scholar
• 7 Gedulin BR, Jodka CM, Herrmann K, Young AA. Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist, AC187. Regul Pept 2006; 137: 121-127
  CrossrefPubMedGoogle Scholar
• 8 Roth JD, Hughes H, Kendall E, Baron AD, Anderson CM. Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression. Endocrinology 2006; 147: 5855-5864
  CrossrefPubMedGoogle Scholar
• 9 Ryan G, Briscoe TA, Jobe L. Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes. Drug Des Devel Ther 2009; 2: 203-214
  PubMedGoogle Scholar
• 10 Malkov D, Angelo R, Wang HZ, Flanders E, Tang H, Gomez-Orellana I. Oral delivery of insulin with the eligen technology: mechanistic studies. Curr Drug Deliv 2005; 2: 191-197
  CrossrefPubMedGoogle Scholar
• 11 Beglinger C, Poller B, Arbit E, Ganzoni C, Gass S, Gomez-Orellana I, Drewe J. Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3-36: a proof-of-concept study in healthy subjects. Clin Pharmacol Ther 2008; 84: 468-474
  CrossrefPubMedGoogle Scholar
• 12 Reidelberger RD, Kelsey L, Heimann D. Effects of amylin-related peptides on food intake, meal patterns, and gastric emptying in rats. Am J Physiol Regul Integr Comp Physiol 2002; 282: R1395-R1404
  PubMedGoogle Scholar
• 13 Wielinga PY, Alder B, Lutz TA. The acute effect of amylin and salmon calcitonin on energy expenditure. Physiol Behav 2007; 91: 212-217
  CrossrefPubMedGoogle Scholar
• 14 Chelikani PK, Haver AC, Reidelberger RD. Effects of intermittent intraperitoneal infusion of salmon calcitonin on food intake and adiposity in obese rats. Am J Physiol Regul Integr Comp Physiol 2007; 293: R1798-R1808
  CrossrefPubMedGoogle Scholar
• 15 Henriksen K, Bay-Jensen AC, Christiansen C, Karsdal MA. Oral salmon calcitonin – pharmacology in osteoporosis. Expert Opin Biol Ther 2010; 10: 1617-1629
  CrossrefPubMedGoogle Scholar
• 16 Karsdal MA, Henriksen K, Bay-Jensen AC, Molloy B, Arnold M, John MR, Byrjalsen I, Azria M, Riis BJ, Qvist P, Christiansen C. Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials. J Clin Pharmacol 2011; 51: 460-471
  PubMedGoogle Scholar
• 17 Buclin T, Cosma RM, Burckhardt P, Azria M, Attinger M. Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J Bone Miner Res 2002; 17: 1478-1485
  CrossrefPubMedGoogle Scholar
• 18 Bagger YZ, Tanko LB, Alexandersen P, Karsdal MA, Olson M, Mindeholm L, Azria M, Christiansen C. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone 2005; 37: 425-430
  CrossrefPubMedGoogle Scholar
• 19 Tanko LB, Bagger YZ, Alexandersen P, Devogelaer JP, Reginster JY, Chick R, Olson M, Benmammar H, Mindeholm L, Azria M, Christiansen C. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res 2004; 19: 1531-1538
  CrossrefPubMedGoogle Scholar
• 20 Feigh M, Henriksen K, Andreassen KV, Hansen C, Henriksen JE, Beck-Nielsen H, Christiansen C, Karsdal MA. A novel oral form of salmon calcitonin improves glucose homeostasis and reduces body weight in diet-induced obese rats. Diabetes Obes Metab 2011; 13: 911-920
  CrossrefPubMedGoogle Scholar
• 21 Roth JD, Roland BL, Cole RL, Trevaskis JL, Weyer C, Koda JE, Anderson CM, Parkes DG, Baron AD. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci USA 2008; 105: 7257-7262
  CrossrefPubMedGoogle Scholar
• 22 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
  Google Scholar
• 23 Twery MJ, Obie JF, Cooper CW. Ability of calcitonins to alter food and water consumption in the rat. Peptides 1982; 3: 749-755
  CrossrefPubMedGoogle Scholar
• 24 Morley JE, Flood JF. An investigation of tolerance to the actions of leptogenic and anorexigenic drugs in mice. Life Sci 1987; 41: 2157-2165
  CrossrefPubMedGoogle Scholar
• 25 Chelikani PK, Haver AC, Reidelberger RD. Effects of intermittent intraperitoneal infusion of salmon calcitonin on food intake and adiposity in obese rats. Am J Physiol Regul Integr Comp Physiol 2007; 293: R1798-R1808
  CrossrefPubMedGoogle Scholar
• 26 Pilon G, Ruzzin J, Rioux LE, Lavigne C, White PJ, Froyland L, Jacques H, Bryl P, Beaulieu L, Marette A. Differential effects of various fish proteins in altering body weight, adiposity, inflammatory status, and insulin sensitivity in high-fat-fed rats. Metabolism 2011; 60: 1122-1130
  CrossrefPubMedGoogle Scholar
• 27 Trevaskis JL, Turek VF, Wittmer C, Griffin PS, Wilson JK, Reynolds JM, Zhao Y, Mack CM, Parkes DG, Roth JD. Enhanced amylin-mediated body weight loss in estradiol-deficient diet-induced obese rats. Endocrinology 2010; 151: 5657-5668
  CrossrefPubMedGoogle Scholar
• 28 Baskin DG, Figlewicz LD, Seeley RJ, Woods SC, Porte Jr D, Schwartz MW. Insulin and leptin: dual adiposity signals to the brain for the regulation of food intake and body weight. Brain Res 1999; 848: 114-123
  CrossrefPubMedGoogle Scholar
• 29 Young AA, Wang MW, Gedulin B, Rink TJ, Pittner R, Beaumont K. Diabetogenic effects of salmon calcitonin are attributable to amylin-like activity. Metabolism 1995; 44: 1581-1589
  CrossrefPubMedGoogle Scholar
• 30 Greeley Jr GH, Cooper CW, Jeng YJ, Eldridge JC, Thompson JC. Intracerebroventricular administration of calcitonin enhances glucose-stimulated release of insulin. Regul Pept 1989; 24: 259-268
  CrossrefPubMedGoogle Scholar
• 31 Kapitza C, Zijlstra E, Heinemann L, Castelli MC, Riley G, Heise T. Oral insulin: a comparison with subcutaneous regular human insulin in patients with type 2 diabetes. Diabetes Care 2010; 33: 1288-1290
  CrossrefPubMedGoogle Scholar
• 32 Potes CS, Turek VF, Cole RL, Vu C, Roland BL, Roth JD, Riediger T, Lutz TA. Noradrenergic neurons of the area postrema mediate amylin’s hypophagic action. Am J Physiol Regul Integr Comp Physiol 2010; 299: R623-R631
  CrossrefPubMedGoogle Scholar
• 33 Potes CS, Lutz TA. Brainstem mechanisms of amylin-induced anorexia. Physiol Behav 2010; 100: 511-518
  CrossrefPubMedGoogle Scholar
• 34 Pilon G, Ruzzin J, Rioux LE, Lavigne C, White PJ, Froyland L, Jacques H, Bryl P, Beaulieu L, Marette A. Differential effects of various fish proteins in altering body weight, adiposity, inflammatory status, and insulin sensitivity in high-fat-fed rats. Metabolism 2011; 60: 1122-1130
  CrossrefPubMedGoogle Scholar